Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well buddy. Caddy? I live right across the street from a golf coarse. Seldom play because I am a wacker for the weeds.
I have accumulated all I need on this stock 126,000 shares. but yes,there are many still adding shares so 1.28 works.
Hypi For those who are still trying to accumulate shares this is welcomed news.
Paul Nice conclusions to draw from EOM
Lem Quite to the contrary on share buying. Just in my immediate spear of influence and family members we own around 310,000 shares. Plus I have several colleagues that have bought in over the last few months. Why do you suppose folks are adding positions? Answer:
To be in position with anticipated SUNRISE APPROVAL.
Two years from now folks are going to look at the chart on PPHM
and be glad they bought in.
EXACTLY, including PPHM execs!_They ain't buying.
Quote:
No wonder why no one wants to buy these shares.
Loof I see three rockets prepping for lift off. I have a special bottle of champagne to take on board to celebrate the launch date.
Sounds like a great plan. I have 126,000 shares so I would be looking at over 3 mil less taxes. I may leave a few thousand in
encase this goes BIG guns. In my opinion it is very possible.
Enough to fill up the calculater with a nice set of numbers followed by a bunch of zero's I am sure.
Couch You have been posting often about having a 10 bagger in bavi. I completely disagree with you in one respect. It will be a 10 bagger for you but I am holding for a 25 bagger. Just saying...
It is Friday evening, time to loosen up the collar and grab a cold one. GLTU
Yes looking at PPHM through the windshield now and not the rear view mirror. Like the new view.
High confidence:
…R.Garnick: “This was a highly collaborative effort with the FDA; this trial, when combined with Bavi’s supporting data to date, could be sufficient to support a future BLA submission."
CAD Your are correct. I personally have a very diversified portfolio. Hopefully most do here. IF not, My gut tells me they are going to be lucky this go around with their eggs. IMO
MD I have 126,000 shares because the future looks better then the past with PPHM. GLTA
Andy Let me second that high five.
Good deal more exposure.
Endo
That deal back in Jan 7th. 2012 with BMY buying inhibitex did it interfere with Avid agreements or was inhibitex no longer in contractual agreement then? No time to research now.
Agreed and the source for bavi on that slide was accessed on March 24th 2014 per source at bottom of slide. The application date of this information on this slide unknown but April 15,2015 was the completion date for the entire slide presentation.
How old is slide? Very least before Bavi information accessed March 24, 2014 from clinicaltrials.com
Loof Careful we do not want the little green men to come. LOL
The rocket is in preparation for launch and count down is about to commence.
Linear? non linear? how about vertical to $25 a SH
djohn
The expansion of Avid should alleviate some of this dilution.
FIREFOX My thoughts earlier when reading PR'S yesterday. Thanks for posting it
The real point I am making is that it shows a high degree of confidence in the Sunrise results within the PPHM Mgmt. team if they are already publicly announcing that future studies will be open label.
Obviously the data from these trails goes into the BLA for SUNRISE to develop supporting data.
Liver is finished IMO. Gone the way of the pancreatic trial. Positive, but data not strong enough in the ever changing landscape to justifying spending own bucks. JMO.
IFU Caribbean Island colors.
BIO never mind. I think I figured it out with abstract information below.
Background: Options for advanced non-SQ NSCLC patients (pts) who progress after platinum-based doublet chemotherapy (PT-DC) are limited, with minimal improvement in overall survival (OS). We report results from a randomized, global phase III study of NIVO, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, vs DOC in pts with advanced non-SQ NSCLC after failure of PT-DC and tyrosine kinase inhibitor, if eligible. Methods: Pts were randomized to NIVO 3 mg/kg Q2W (n=292) or DOC 75 mg/m2 Q3W (n=290) until progression or discontinuation due to toxicity/other reasons. Primary objective was OS; Secondary objectives were investigator-assessed objective response rate (ORR; per RECIST v1.1), progression-free survival (PFS), efficacy by PD-L1 expression, quality of life, and safety. Results: NIVO demonstrated superior OS (HR=0.73; 96% CI: 0.59, 0.89; P=0.00155) and improved ORR (19.2% vs 12.4%; P=0.0235). HR for PFS was 0.92 (95% CI: 0.77, 1.11; P=0.393). PD-L1 expression was associated with benefit from NIVO (Table). In PD-L1+ pts, NIVO showed improved efficacy across all endpoints at predefined 1%, 5%, and 10% cut- points. Grade 3–5 drug-related AEs occurred in 10.5% (30/287) of NIVO and 53.7% (144/268) of DOC pts. No deaths were related to NIVO vs 1 DOC-related death. After discontinuation, 42.1% of NIVO and 49.7% of DOC pts received subsequent systemic therapy. Conclusions: NIVO demonstrated superior OS vs DOC in pts with advanced non-SQ NSCLC after failure of PT-DC. The safety profile of NIVO 3 mg/kg Q2W was favorable vs DOC. NIVO demonstrated survival benefit across histologies in two randomized phase III trials. Clinical trial information: NCT01673867
Bio,
I am looking at all of these expression levels and trying to extrapolate how bavi factors in comparison. I know Bavi has a much broader efficacy and response with patients. Assuming great results from Sunrise, could you provide some comparative details. If you wish. Thanks.
Efficacy Summary: Median Overall Survival by PD-L1 Expression
Opdivo Docetaxel
=1% PD-L1 expression level
HR = 0.59 (95% CI, 0.43- 0.82)
17.2 months 9.0 months
<1% PD-L1 expression level
HR = 0.90 (95% CI, 0.66- 1.24)
10.4 months 10.1 months
=5% PD-L1 expression level
HR = 0.43 (95% CI, 0.30-0.63)
18.2 months 8.1 months
<5% PD-L1 expression level
HR = 1.01 (95% CI, 0.77- 1.34)
9.7 months 10.1 months
=10% PD-L1 expression level
HR = 0.40 (95% CI, 0.26-0.59)
19.4 months 8.0 months
<10% PD-L1 expression level
HR = 1.00 (95% CI, 0.76- 1.31)
9.9 months 10.3 months
Front page Wash Post article on immunotherapy combo treatments
By Lenny Bernstein and Brady Dennis May 28 at 4:37 PM
old news but interesting
...........................
One advance may involve using checkpoint inhibitors in combination with each other, with other drugs that target specific tumors or with chemotherapy. In a study of 142 patients published May 21 in the New England Journal of Medicine, researchers showed a startling 61 percent response rate when they treated one kind of melanoma with both ipilimumab and nivolumab, although the side effects were worse than they were for people who took ipilimumab alone.
“I do think that it is a very amazing time in our field,” said Jedd D. Wolchok, associate director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering and one of the researchers in that study. “It’s taken a long time for us to get here. There were many decades of challenge to prove that modulation of the immune system is a standard and impactful way to treat cancer.
“But now we have shown that. And now the remaining job is to extend the benefits to more patients and more types of cancer.”
Here is link
http://www.washingtonpost.com/national/health-science/unleashing-the-immune-system-in-the-fight-against-cancer/2015/05/28/c0fb2694-00bf-11e5-805c-c3f407e5a9e9_story.html
cheynew
If I understand this correctly PPHM can purchase back all preferred shares at par value without conversion on 2/11/17 or when acquired. If they hit the strike price @ 3$ prior to this it can/will convert into 8.33 common. Correct??
Since PPHMP is a convertible issue, there is some potential upside if Bavituximab is successful. Each share of PPHMP is optionally convertible into 8.33 shares of PPHM. PPHM is now well below the $3 strike price, but large stock moves are not uncommon in the pharmaceutical sector. Note that PPHMP can be called at par on 2/11/2017 or immediately if the company is acquired.
RM It feels like their loading the primer for a run. Who knows?
TOG
Gale is active in Pre this morning.
GALE has been acting similarly. Both Friday and today AH.
AH 444548 still going
Seagull2
This will be a good way to start the day off.
Today and over the next few months PPHM will be the best investment in the Biotech space. The wise thing to do here is to buy more each month especially if the PPS retreats from current prices. This is all about taking advantage of one's time and making his/her retirement a paradise. I should have some funds cleared to take advantage tomorrow if we retreat slightly from current prices. Sold some HZNP to roll over into PPHM. One day we will all get up and PPHM will be trading at double or triple the current prices; and $1.30 will never be seen again. The fact that we have more time to accumulate these shares is a blessing. We could not be more blessed.
PPHMtoolong
Thanks.
we know things are moving along at Peregrine, because we know they are honest people trying their best. I have followed the company for a lot of years, and I have no reason to doubt their sincerity. This does not mean the Sunrise trial is a sure thing. In my view it is a probable thing, but we have to wait for the hard data to prove its value.
DD on the other hand makes no effort to conceal his hyper negative attitude toward all things Peregrine. You might remember his assertions that Bavi was a placebo drug, the FDA would never greenlight a Bavi Phase III, etc.
Peregrine's saying Sunrise is on track agrees with the 160 open sites on clinicaltrials.gov. Anyone who doubts management's basic honesty should have evidence to support their claim not just a history of error-riddled opinions.
GLTA, Paul
Jake17 Should be against the law for Sierra to predict such nonsense. Being facetious. Do the opposite for best results. LOL
BIO They had a 25/1 split in 2011. Guess it was time in rein it all back in and then some.
Stone This statement would indicate unblinding-2nd look-in.
He simply stated something along the lines of they hoped/expected to have some data from a look in in early 2016
Bottom line- The FDA approved drugs on the market have various side effects. Bavi has demonstrated through its trails a profile of efficacy and safety. Hence the reason for combo trials. One patient's email however deciphered does not preclude SUNRISE FDA approval one iota. Hope the patient is well.
Jeff, I was thinking about you yesterday. Glad you got more shares on the cheap before the SUN RISES. I am up over 126K now. I hit my limit for this one. Need to focus on the other stocks in my portfolio.
Real Actually I sold 7k--Filled 1800 @1.41 & 5200 @1.39 Bought back in @1.31 today to increase my shares.
VOL CP'S imagination is the better deal. I'll take it.